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The Myth Of Making Inferences For An
Overall Treatment Efficacy With Data From
Multiple Comparative Studies Via
Meta-analysis
Takahiro Hasegawa, Brian Claggett, Lu Tian, Scott D. Solomon, Marc A. Pfeffer,
and Lee-Jen Wei

Abstract

Meta analysis techniques, if applied appropriately, can provide a summary of the
totality of evidence regarding an overall difference between a new treatment and a
control group using data from multiple comparative clinical studies. The standard
meta analysis procedures, however, may not give a meaningful between-group
difference summary measure or identify a meaningful patient population of interest, especially when the fixed effect model assumption is not met. Moreover,
a single between-group comparison measure without a reference value obtained
from patients in the control arm would likely not be informative enough for clinical decision making. In this paper, we propose a simple, robust procedure based
on a mixture population concept and provide a clinically meaningful group contrast summary for a well-defined target population. We use the data from a recent
meta analysis for evaluating statin therapies with respect to the incidence of fatal
stroke events to illustrate the issues associated with the standard meta analysis
procedures as well as the advantages of our simple proposal.
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1. Introduction
In comparing two treatments (for example, a new intervention vs.
standard care) using the data from multiple studies, meta
analysis can be a powerful tool to combine information across the
studies for evaluating an overall group difference. As an example,
recently Taylor et al. performed an extensive meta analysis to
assess the effects, both risk and benefit, from various statins [1].
The meta analysis included randomized controlled clinical trials of
statins vs. placebo or the standard care control with minimum
duration of one year and follow-up of six months in people without
a past history of cardiovascular disease (CVD). There are various
outcome variables considered in their meta analysis. Here we
consider the case with the fatal stroke event as the outcome of
interest. In Table 1, we report the data from three studies:
CARDS, JUPITER and WOSCOPS. The observed risk ratios
(RRs) of statin to control across the three studies range from 0.14
to 1.43. A standard method for combining these RRs would be
based on the Mantel–Haenszel procedure assuming a fixed-effect
model [2, 3]. That is, we assume that the true RRs are the same
across three studies. Under this assumption, the resulting
estimated RR is 1.14 with a 95% confidence interval of (0.78, 1.66),
indicating there is no significantly increased risk for fatal stroke
associated with either treatment option. This estimate is
essentially a weighted average of the observed study-specific RRs.
The weights depend on the data. When the fixed-effect model
assumption is plausible, one may interpret that for each study
population in Table 1, the increase in risk associated with the
statin could be about 14%. Note that since there is no summary
measure for the event rate across the studies for either treatment
group, it is not clear how to interpret whether or not a 14% risk
increase would be clinically meaningful. This is a common
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problem for the conventional meta analysis even when the fixed
effect model assumption is plausible.

Table 1. Risk of fatal stroke events for statin and standard care
Control
Study

Statin

N

Events

N

CARDS [4]

1412

7

1429

JUPITER [5]

8901

6

8901

WOSCOPS [6]

3293

37

3302

* The risk ratio is defined as the event rate
rate in the control group.

Risk ratio
(RR)*
Events
[95% CI]
0.14
1
[0.02-1.15]
0.50
3
[0.13-2.00]
1.43
53
[0.94-2.17]
in the statin group divided by the event

Empirically, Taylor et al. [1] found that the above fixed-effect model is
not appropriate for the data in Table 1, evidenced by a p-value of 0.04
from a standard heterogeneity lack of fit test. The weights used to
derive the fixed-effect estimate of 1.14 depend on the underlying studyspecific event rates in a rather complex, data-dependent form. When the
fixed-effect assumption is not reasonable, it is difficult, if not
impossible, to interpret the meaning of the weights used or to what
patient population the estimated RR would apply.
Instead of using the fixed effect model, Taylor et al. utilized a
random-effects model [7] to combine the data across the studies. Under
the random-effects framework, one assumes that the three observed
studies were random samples from a hypothetical “super-population” of
studies and that the true treatment contrast may differ from one study
to another but follows a specific distribution across the super-population
of studies. The resulting RR estimate, allowing for such heterogeneity
between studies, is a 37% decrease in risk associated with statin use
3
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and with a wide 95% confidence interval [RR=0.63, (0.18-2.23)]. It is
interesting to note that numerically the RR estimates for the fixed and
random effects appear to be quite different. This estimate is also a
weighted average of observed study-specific risk ratios and the weights
used depend on the underlying study-specific event rates. Note that the
random effect model procedure may be considered as a mixture
population approach as discussed using Bayesian hierarchical modeling
approaches [8, 9].
There are several issues with this random effects model approach.
Firstly, the resulting confidence interval when the number of studies is
small (here, only three studies in the meta analysis) may not have the
correct coverage level, a well-known fact in the statistical literature [10,
11]. This limitation has recently been pointed out in an excellent,
extensive review article by Cornell et al. [12] in the clinical literature
along with three specific alternative methods which attempt to account
for the increased uncertainty induced by between-study differences.
However, these improved alternatives do not address a fundamental
issue regarding random-effects meta analysis. That is, the previously
mentioned hypothetical “super-population” of studies is generally not a
well-defined or easily understood concept. For example, it is difficult to
determine if the inference results based on a random effects model
would be applicable to a new study population since there is often no
clear rule to determine if the new study of interest belongs to the
“super-population” of studies. Because of this, the resulting estimated
RR cannot be viewed as a valid estimate of the true RR for any of the
three patient populations or a future target population. Even if there is
a well-defined super-population, a complete summary of the betweengroup difference cannot be conveyed without a description of the full
distribution of the estimated random effects, not just its center (e.g.,
average) value [13]. However, this approach poses additional technical
challenges and has been rarely employed in practice. Furthermore, the
validity of the resulting point and interval estimates requires a strong
4
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distributional assumption (for example, normal distribution for the
random effects) regarding the true RR's across all of the studies from
the super-population, an assumption that may easily be misspecified
and is difficult to justify empirically. Lastly, as in the fixed-effect
modeling approach, there is no obvious summary event rate estimate
for each strategy to interpret whether a potential 37% reduction in risk
for the statins relative to the control would represent a clinically
meaningful difference.
As described, the standard procedures for meta analysis do not
identify a target patient population of interest or utilize a clinically
meaningful summary to quantify the between-group difference,
especially when the fixed effect model assumption is not met. Therefore,
there is a resurrected interest in conducting simple pooling analysis,
where data from individual studies are pooled by the treatment group,
and analyzed as if from a single study. However, the pooling analysis
still does not identify a target population, Moreover, when the
treatment allocation rates vary across individual studies, this analysis
may yield spurious results [14, 15].
In the next section, we use the above example to illustrate a simple,
robust procedure via the well-known mixture model approach [16, 17] to
combine information across multiple studies. This procedure can
identify a target study population and a simple, meaningful group
contrast summary measure with an overall estimated event rate from
the control arm, which can be used as a reference value for clinical
decision making. In this paper, we first consider the case that only
summary data for the patients’ baseline covariates and outcomes are
available from individual studies. To combine information for the
between-group comparisons, the ideal situation is to have patient-level
data from individual studies so that we may be able to make efficient
inference for a target population with a pre-specified joint covariate
distribution or its summaries thereof. We discuss a potential approach
5
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to handle the case that we are interested in a pre-specified target
population. We use the data from a large global cardiovascular clinical
trial by treating each sub-study conducted in a country involved as the
individual study in the meta analysis.
2. Identifying a mixture, target population and estimating an overall
group difference
To illustrate our simple approach, consider the aforementioned
comparison of fatal stroke rates between the standard care and statins.
Note that like other meta analyses, there was no target population of
interest pre-specified in this meta analysis. The selection process of
studies was driven by the availability of data [4–6]. The first question is
whether we can use available information in the literature to identify a
potential target population from this specific meta analysis. For each of
the three clinical studies, there is a parent patient population well
specified in its study protocol (for example, via the study inclusion and
exclusion criteria based on the subjects' baseline covariates). However,
only summary data including the study patients’ baseline
characteristics for individual studies are available in the publications.
In Table 2, we provide an empirical summary of some of the patients'
baseline characteristics (e.g., average age, proportion of males, average
BMI, average LDL, average SBP and DBP) from each of the three
studies available in the literature. These summaries empirically
characterize the patients’ profiles of the underlying study populations.
Note that these three study populations seem rather different, for
example, with respect to the proportion of males in each study (ranging
from 62% to 100%) as well as patients' average LDL cholesterol
(ranging from 2.79 mmol/L to 4.97 mmol/L). Within the random effects
modeling framework, it is not clear from which “super population” these
studies were selected.
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Table 2. A summary of baseline characteristics from each of the three
studies
Mean
Mean
Mean
Mean
Mean
Male
Study
age
BMI*
LDL*
SBP*
DBP*
(%)
(years)
(kg/m2) (mmol/L) (mm Hg) (mm Hg)
CARDS [4]
62
68
29
3.03
144
83
JUPITER [5]
66
62
28
2.79
134
80
WOSCOPS [6]
55
100
26
4.97
135
84
* BMI = body mass index. LDL = low-density lipoprotein. SBP = systolic blood
pressure. DBP = diastolic blood pressure.

A possible target population can be constructed via a mixture of 𝐾
individual study populations in the meta analysis. To this end, assume
that 𝑃𝑘 and 𝐹𝑘 (𝒙) are, respectively, the 𝑘 th patient population and the
corresponding cumulative joint distribution function of the patients'
baseline covariate vector 𝒙 = (𝑥1 , ⋯ , 𝑥𝑝 )′ for 𝑘 = 1, ⋯ , 𝐾. Note that these
populations may be overlapped. The 𝐹𝑘 (𝒙) may be estimated with the
patients’ level data from the 𝑘 th study, 𝑘 = 1, ⋯ , 𝐾. If there are no
patient level data, the summaries in Table 2 may be used to
characterize a target population. A mixture population ℙ of these 𝐾
populations with a set of nonnegative weights 𝒘 = (𝑤1 , ⋯ , 𝑤𝐾 )′, where
∑𝐾
𝑘=1 𝑤𝑘 = 1 , represents a patient population consisting of these 𝐾
populations. A typical subject of this mixing population is obtained as
follows. First, we generate a multinomial random variable from
{1, ⋯ , 𝐾} with cell probabilities {𝑤𝑘 }. Suppose that the realization is 𝑘,
then the subject is chosen randomly from 𝑃𝑘 . The cumulative
distribution function of the covariates of this mixture, target population
would be 𝐹0 (𝒙) = ∑𝐾
𝑘=1 𝑤𝑘 𝐹𝑘 (𝒙) . In the following, we assume that the
parameter of interest is 𝜃 = 𝑔(𝑝1 , 𝑝0 ) , a contrast between 𝑝1 and 𝑝0 ,
where 𝑝𝑗 is the underlying event rate of group 𝑗 in the mixture
population ℙ. If 𝑔(𝑥, 𝑦) = 𝑥/𝑦, then 𝜃 is RR, as used in the example
above.
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To make inference about 𝜃, one needs to specify the target population
𝑃0 by choosing the mixing proportions. The mixing weights {𝑤𝑘 } can be
chosen to be reflective of the relative “clinical importance and
relevance” of the individual study populations. As an example using the
above meta analysis, we might consider those three study populations
to be equally important with a weight of 1/3 each. With this set of
mixing weights, the average age, proportion of males, average BMI,
average LDL, average SBP and DBP are approximately 61 years, 77%
male, 28 kg/m2, 3.60 mmol/L, 138 mmHg, and 82 mmHg, respectively in
this “equal-mixture” target population. If more detailed information is
available from the publications of these three parent studies, one can
further characterize this target population in terms of other relevant
patients’ characteristics. For instance, the standard deviation for
continuous variables could be obtained for this mixture population
based on the standard deviations reported in the papers of the three
studies if available.
The inference for 𝜃 in this case is straightforward. For example, (𝜃̂ −
𝜃) can be approximated by a mean zero normal distribution with a
variance of
𝐾
2

𝜎̂ =

𝑔̇12 (𝑝̂1 , 𝑝̂0 ) ∑
𝑘=1

𝐾

𝑤𝑘2 𝑝̂ 𝑘1 (1 − 𝑝̂ 𝑘1 )
𝑤𝑘2 𝑝̂ 𝑘0 (1 − 𝑝̂ 𝑘0 )
2 (𝑝̂
+ 𝑔̇ 0 1 , 𝑝̂ 0 ) ∑
,
𝑛𝑘1
𝑛𝑘0

where 𝜃̂ = 𝑔(𝑝̂1 , 𝑝̂0 ), 𝑝̂𝑗 =

𝑘=1

∑𝐾
𝑝𝑘𝑗
𝑘=1 𝑤𝑘 𝑝̂ 𝑘𝑗 , ̂

is the observed event rate in

the group j of the 𝑘 th study with 𝑛𝑘𝑗 observations and 𝑔̇ 𝑗 (𝑝1 , 𝑝0 ) is the
partial derivative of 𝑔(𝑝1 , 𝑝0 ) with respect to 𝑝𝑗 . The confidence interval
for 𝜃 can then be constructed accordingly.
Now, with the data from the above fatal stroke meta analysis, for this
“equal-mixture” population ℙ, we may first estimate the event rate for
the control group using a simple average of its three observed event
rates: 0.50%, 0.07%, and 1.12% from Table 1. This results in an
estimate of 0.56%:
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(0.50%×33.3%) + (0.07%×33.3%) + (1.12%×33.3%) = 0.56%.

Similarly we obtain an average event rate for the statin arm, which is
0.57%. Then the underlying RR between the two treatment groups is
the ratio of the two event rates can be estimated as 0.57%/0.56% (=1.01)
with a 95% confidence interval of (0.67, 1.53). Note that the
interpretation of the estimated RR of 1.01, coupled with the two
estimated event rates 0.57% and 0.56% for the statin and control is
more informative for clinical decision making. Moreover, this simple
mixture approach allows for the use of different metrics to quantify the
between-group difference. For instance, one can easily obtain the
absolute risk difference estimate and numbers needed to treat (NNT) or
harm (NNH). For this specific mixture population, the risk difference
would be 0.01% with a 95% confidence interval of (-0.22%, 0.24%).
Rather than assuming that each study population is equally clinically
relevant, we may consider a scenario that the study sample size is
reflective of how common certain types of patients are in the general
population, suggesting that the study weights should be proportional to
the study sample size. For the present example, the study weights
would be 10.4%, 65.4%, and 24.2%, respectively. In this "study size
mixture" target population, the average age, proportion of males,
average BMI, average LDL, average SBP and DBP are approximately
63 years, 72% male, 28 kg/m2, 3.34 mmol/L, 135 mmHg, and 81 mmHg,
respectively. The event rates are estimated to be 0.42% for the statin
group and 0.37% for the control group. Then the RR is 1.14 with a 95%
confidence interval of (0.77, 1.67). Note that for this mixture population,
the observed event rates are lower than those for the mixture
population with the equal mixing weights discussed above. The
summaries of the patients’ baseline characteristics indicate that this
second population contains relatively more females and has lower
average LDL and blood pressure values. We may be able to differentiate
these two populations further if more information about the patients’
9
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baseline characteristics is available in the individual study-specific
publications.
3. Identifying a mixture population from studies in meta analysis to
match a pre-specified target population
A key principle in the conduct of a clinical study is to define the patient
population first, then collect data in order to make inference about a
certain characteristic of this population. Ideally, meta analyses should
follow this principle as well. Once a well-defined target patient
population has been established, for instance, with respect to the
distribution 𝐹0 (𝒙) of the patients' baseline variables, the investigator
may select studies for the meta analysis whose parent populations are
similar or relevant to the target patient population with respect to the
distribution of the vector of baseline variables 𝒙. Now, let 𝐹̂𝑘 (𝒙) be the
empirical distribution function for the 𝑘 th study, 𝑘 = 1, ⋯ , 𝐾. Then, in
̂ = (𝑤
theory, one may choose the mixing weights 𝒘
̂1 , ⋯ , 𝑤
̂ 𝐾 )′ such that
𝐾
∑𝑘=1 𝑤
̂𝑘 𝐹̂𝑘 (𝒙) ≈ 𝐹0 (𝒙), for all 𝒙 in the support of the covariate vector.
Note that the above equations may be relaxed by matching certain sets
of moments of covariate variables, for example, via the mean values of
covariates. In this section, we assume that we have the patient level
data from individual studies.
We use the data from a clinical trial, VALsartan In Acute myocardial
iNfarcTion (VALIANT) trial, to illustrate our proposal [18]. This study
is a multi-center double-blind randomized clinical trial comparing the
effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor
captopril and the combination of the two on mortality/mobility in
patients with myocardial infraction, heart failure or both. There are
14703 patients with 30 baseline covariates from 24 countries. We treat
each sub-study conducted in a country as a “study” for the purposes of
meta-analysis. For illustration, the outcome of interest is the event of
the first hospitalization or death during the first 18 months of the
10
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follow-up and we compare the monotherapy treatments with the
combination therapy by grouping the patients receiving either valsartan
or captopril alone into a single arm. To simplify the illustration, five
baseline covariates (age, history of diabetes, history of heart failure,
history of stroke and usage of other diuretics) were selected as the most
statistically important covariates via the standard logistic regression
with the entire dataset. There are 9737 and 4843 patients with
complete covariate information in the monotherapy and combination
therapy arms, respectively. The empirical means of those five baseline
factors by country are summarized in Table 3.

Table 3. A summary of baseline characteristics from each of the 24
countries in VALIANT study.

Country (n)

Age, yrs
(mean)

Diabetes
(%)

Argentina (633)
Australia (306)
Austria (26)
Belgium (66)
Brazil (213)
Canada (1081)
Czech (204)
Germany (323)
Denmark (674)
Spain (122)
France (161)
United Kingdom (820)
Hungary (396)
Ireland (38)
Italy (739)
Netherlands (253)
Norway (263)
New Zealand (134)
Poland (342)
Russian Federation (3120)
Slovakia (184)

62.2
65.9
62.5
67.4
63.1
66.8
65.7
63.4
69.2
66.5
65.5
64.4
61.9
68.5
66.4
67.9
70.6
67.9
63.0
63.6
62.8

20.2
26.8
23.1
22.7
23.5
29.4
25.5
21.4
24.5
34.4
19.3
21.2
14.4
21.1
20.0
24.5
27.8
29.1
28.1
36.2
23.4

Heart
failure
(%)
7.7
13.1
7.7
4.5
12.7
15.8
6.4
9.3
13.2
21.3
8.1
5.1
7.8
7.9
7.0
5.5
17.1
8.2
14.0
24.1
9.2

Stroke
(%)
3.5
6.9
11.5
6.1
7.5
6.7
4.9
5.3
9.3
5.7
5.6
4.1
4.0
7.9
3.4
4.7
5.7
6.7
6.1
7.0
4.9

Usage of
other
diuretics (%)
34.9
54.9
50.0
24.2
55.9
60.3
36.3
52.3
73.1
46.7
72.0
47.1
63.6
47.4
59.5
65.2
91.3
67.9
43.9
43.8
33.3
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Sweden (485)
72.1
29.3
12.4
U.S.A. (3939)
63.7
29.4
16.0
South Africa(58)
59.5
19.0
3.4
Target 1*
65.3
28.2
15.1
Target 2
61.0
25.0
10.0
* The moments of this target population are set to be
counterparts of all participants from Europe.

7.4
73.2
6.4
43.4
0.0
60.3
6.1
53.2
5.0
45.0
same as observed

In practice, the target population is generally described via certain
summaries of individual covariates’ profiles (for example, the mean and
standard deviation for a continuous covariate). Therefore, to obtain the
weights {𝑤
̂𝑘 }, one may minimize the distance
𝐿

2

𝐾

𝑀(𝒘) = ∑ [∑ 𝑤𝑘 ∫ 𝑚𝑙 (𝒙)𝑑𝐹̂𝑘 (𝒙) − ∫ 𝑚𝑙 (𝒙)𝑑𝐹0 (𝒙)] ,
𝑙=1 𝑘=1

subject to the constraint
𝐾

∑ 𝑤𝑘 = 1 and 𝑤𝑘 ≥ 0, 𝑘 = 1, ⋯ , 𝐾,
𝑘=1

where 𝑚𝑙 (𝒙) is a function of the covariate vector for example,
𝐸{𝑚𝑙 (𝒙)} can be the first or second moment of a single covariate. That is,
we approximate the distribution 𝐹0 (𝒙) by a mixture of individual studyspecific empirical moments. When 𝐿 is small, one may not have enough
information to uniquely define the mixture population, that is, there are
multiple sets of weights matching the target population perfectly, i.e.,
̂
∑𝐾
𝑘=1 𝑤𝑘 ∫ 𝑚𝑙 (𝒙)𝑑𝐹𝑘 (𝒙) = ∫ 𝑚𝑙 (𝒙)𝑑𝐹0 (𝒙), 𝑙 = 1, ⋯ , 𝐿.
In the VALIANT study, if we let the covariate means of the target
population be the observed empirical averages of all participants from
Europe (see Target 1 of Table 3), i.e., 𝑚𝑙 (𝒙) = 𝑥𝑙 , 𝑙 = 1, ⋯ , 5, there are
multiple ways to form the mixture population matched with the desired

12
http://biostats.bepress.com/harvardbiostat/paper207

covariate means. For example, it is straightforward to verify that both
weights
̂ 1 =(4.0, 1.7, 0.0, 0.0, 0.0, 7.8, 0.6, 1.6, 5.0, 1.8, 1.5, 5.2, 3.1, 0.3, 6.8,
𝒘
2.2, 5.2, 0.1, 1.0, 20.7, 0.1, 5.0, 26.0, 0.1)%
and
̂ 2 =(3.7, 5.5, 0.3, 0.3, 5.1, 7.4, 2.1, 3.5, 3.4, 12.4, 1.5, 1.0, 2.3, 0.9, 1.9,
𝒘
0.2, 7.0, 1.6, 7.3, 14.5, 4.4, 3.5, 8.6, 1.5)%
can be used to match the specified covariate means. In fact, there are
infinite number of weights {𝑤𝑘 } satisfying the constraints. While all the
candidate weights generate a target population with desired moments,
we may prefer to more efficiently utilize the observed data for making
inferences about the treatment difference. Intuitively, one would assign
a relatively large weight for a large study. Specifically, we may choose
the mixing weight solving the original optimization problem and also
minimizing the loss function
𝐾

𝐷(𝒘) = ∑(𝑤𝑘 − 𝜋𝑘 )2 ,
𝑘=1

where 𝒘 = (𝑤1 , ⋯ , 𝑤𝐾 ) and 𝜋𝑘 is the proportion of the patients from the
𝑘th study/country in the combined patient cohort. In this case, the
̂ 1 given above.
solution is 𝒘
Now, suppose that there is a unique solution 𝒘 to the limit of 𝐷(𝒘)
̂=
subjects to all the constraints, and also a unique solution 𝒘
′
(𝑤
̂ converges
̂1 , ⋯ , 𝑤
̂ 𝐾 ) to 𝐷(𝒘). Under certain regularity conditions, 𝒘
to 𝒘 = (𝑤1 , ⋯ , 𝑤𝐾 )′ in probability as the sample sizes of all studies go to
infinity. Furthermore, if we assume that 0 < 𝑤𝑘 < 1, 𝑘 = 1, ⋯ , 𝐾, then
̂ − 𝒘) can be approximated well by a mean zero Gaussian
(𝒘
distribution. With slight abuse of notation, 𝜃, the parameter of interest,
is the underlying between group contrast in the mixture population
with weights 𝒘. To make inferences about the between-group difference
𝜃, consider the aforementioned heart failure incidence example. For this
case, a consistent estimator for 𝜃 is
13
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𝜃̂ = 𝑔(𝑝̂1 , 𝑝̂0 ),
where
𝐾

𝑝̂𝑗 = ∑ 𝑤
̂ 𝑘 𝑝̂ 𝑘𝑗 , 𝑗 = 0, 1.
𝑘=1

Furthermore, by the delta method, the distribution of (𝜃̂ − 𝜃) can be
approximated by a normal distribution 𝑁(0, 𝜎 2 ). The variance 𝜎 2 can be
estimated via a resampling method, for example, bootstrapping. Note
̂ are also random. One needs the patient level data
that the weights 𝒘
from individual studies to obtain a consistent estimator for this limiting
variance.
̂ 1 , the minimizer of 𝐷(𝒘), as
In the VALIANT example, if we choose 𝒘
the mixing weights, the estimated incidence rate of hospitalization or
death during the first 18 months of the study is 57.43% and 57.65% for
the combination therapy and mono therapy arms, respectively. Thus,
the treatment effect measure of the difference of incidence rates
between the two arms is -0.22%. To obtain a confidence interval, we
bootstrapped individual patients within each of the study to account for
the variations of both the weights and study-specific treatment effect
estimator. The estimated standard error is 0.96% and the corresponding
95% confidence interval is (-2.10%, 1.66%), suggesting that the
treatment effect, if any, is relatively small in magnitude. On the other
hand, if we prefer less variation in weights across studies, we may use
the modified loss function
𝐾

𝐷(𝒘) = ∑(𝑤𝑘 − 𝐾 −1 )2
𝑘=1

to guide the selection of the mixing weight. The resulting mixing
̂ 𝟐 and the estimated treatment effect is 1.67% (-4.81%,
weight is 𝒘
1.73%). Note that the variance of this estimator triples that of the
previous estimator with the weights selected via the study sizes, which
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demonstrates the important role of the study sizes in improving the
precision of the inference procedure.
The requirement of individual patient data for making statistical
inference when the weights are data dependent can be difficult to meet
in practice. However, the individual level data are needed to estimate
̂ and the study-specific treatment effect
the joint distribution of 𝒘
estimates (𝜃̂1 , ⋯ , 𝜃̂𝐾 )′. If we ignore correlations between the two, the
variance of 𝜃̂ can be approximated with only study-level summary data.
In the VALIANT study, the resulting variance estimator is very close to
that based in individual patient data. However, such an observation
may not be reproducible in other settings.
For certain situations, we may not be able to create a mixture of
individual study populations to perfectly match those pre-specified
moments of the target population, especially when 𝐿 ≥ 𝐾. For example,
in VALIANT study, if we consider the second target population in Table
3, representing a younger (mean age 61) and healthier population (25%
diabetic, 10% with heart failure, 5% with stroke, 45% diuretic use) than
the European patients, then there is no set of weights which would
produce a perfect match with 𝑀(𝒘) = 0. If we search for the most
similar mixture population by minimizing 𝑀(𝒘) , then the resulting
population consists of patients only from Austria, Russia Federation,
Slovakia and South Africa. In general, we may check whether the
empirical moments of the resulting mixture population specified above
are similar to those for the target population. If they are not similar in a
practical sense, the resulting mixture population would not be a good
approximation to the target population. In the above example, the
covariate means are 61.9 years for age, 24.5% for diabetic history,
10.2% for history of heart failure, 4.9% for history of stroke and 46.8%
for other diuretics usage, which are close to the specified levels of the
target population. The treatment effect estimator is -3.86% with a
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much wider confidence interval of (-14.61%, 6.89%) based on bootstrap
methods.

It is interesting to note that all the matchable covariate mean vectors
consist the convex hull generated by points in 𝑅𝐿 representing the
observed covariate means in each of the studies. For demonstration
purposes, we consider to match only age and history of diabetes in the
VALIANT study. In this setting, Figure 1 shows the convex hull within
which all the combinations of age and history of diabetes can be
matched using those from the 24 studies. For example, (61 years, 25%)
is within the convex hull and indeed if we weigh Poland, Russia
Federation and South Africa by 3.1% 33.3% and 63.5%, respectively,
then we can match the average age of 61 years and diabetic prevalence
of 25%. The sparseness in weight is a reflection of the fact that (61
years, 25%) is very close to the boundary of the convex hull. It is also
clear that (61 years, 30%) is outside the constraint set and thus there is
no mixture population with an average age of 61 years and a diabetic
prevalence of 30%. However, using our proposal, we may find the best
approximation to the target population, whose mean is (62 years, 29%)
marked on the Figure 1.

Figure 1: Matchable combinations of age and history of diabetes in
Valiant study and the graphic demonstration of approximating an
unmatchable target populatin.
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ESP

0.30

(61, 30%)
(62.0, 29.3%)
SWE

0.25

(61, 25%)

IRL

0.20
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0.35

RUS

0.15

ZAF

HUN
60
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64

66

68

70

72

age

4. Remarks
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For the conventional meta analysis, we obtain each study-specific
between-group risk ratio first, and then combine them across studies
using weights that depend on, for example, study-specific event rates.
The resulting overall estimate and reference population may be difficult
to interpret clinically or may fail to represent a meaningful patient
population. Instead we recommend obtaining an overall event rate
estimate from an interpretable mixture of study populations for each
treatment group first, and then construct the between-group difference
measure. This approach does not require any modeling assumptions
and provides a clinically interpretable empirical group difference
estimate for a well-defined study population. Moreover, this procedure
also provides the overall event rate estimates for two groups (for
example, 0.37% vs 0.42% for fatal stroke incidence for the control and
statin groups), allowing for the interpretation of the relative risk ratio
in a more meaningful way. Note that like other meta analysis methods,
the inference procedure for this simple proposal may not perform well
when there are studies with zero events. An exact inference procedure
may be needed to handle this situation.
It is important to note that the above approach is quite different from
the controversial “pooling analysis.” For pooling analyses, we would
combine the “statin therapy” patients from all three studies to obtain
the event rate estimate, and then similarly for the “control therapy”
patients. Then the RR would be constructed from these two estimated
rates. In our example, the resulting RR estimate would be 1.14 with a
95% confidence interval of (0.78, 1.66), which is not drastically different
from the estimates for the above mixture population with weights
proportional to the study sizes due to the fact that among these three
studies, there is no study with a marked imbalance in sample size
between the two groups. While our proposal is similar to pooling
analysis with respect to simplicity of implementation, our proposal is
flexible with respect to prespecified mixing proportion and importantly,
remains valid when the treatment allocation proportions are different
18
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across individual studies, while the pooling procedure may produce
unreasonable results, reflecting Simpson’s paradox [19]. As an
illustrative example, we consider the well known example of the study
in gender bias among graduate school admissions at UC Berkeley (see
Appendix for data). In the pooling analysis, the overall admission rate
of males was 45% compared to 30% for females, suggesting an
admissions processed that strongly favored male applicants. However,
when applying our method using total number of applications per
department as the weights, the resulting estimates are 39% acceptance
for males and 43% for females, estimates much closer in magnitude and
reversing the original suspected gender discrepancy.
In time-to-event analyses, the conventional meta analysis procedure
is to estimate each study-specific hazard ratio and obtain a weighted
average of those hazard ratio estimates. The interpretability of the
resulting estimate depends on two strong model assumptions: i) the
proportional hazards assumption within each study; and ii) the equality
of all underlying study-specific hazard ratios. With the mixture
population model approach, we cannot obtain a weighted average of the
study-specific hazard functions for each group due to the fact that the
hazard function is not a probability. On the other hand, an alternative
summary measure such as the event rate or the restricted mean
survival time at a specific follow-up time point can be considered for
each group [20, 21]. We may then similarly obtain an estimate based on
an interpretable mixture of these study-specific event rates (or
restricted mean event times) across all studies to construct a group
contrast measure for a target mixture population.
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Appendix: Data Set for Graduate Admissions Example
Department
A
B
C
D
E
F
total

Male
applicants
825
560
325
417
191
373
2691

accepted
512
353
120
138
53
22
1198

Female
applicants
108
25
593
375
393
341
1835

accepted
89
17
202
131
94
24
557
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